[{"orgOrder":0,"company":"Tessera Therapeutics","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Tessera Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.050000000000000003,"dosageForm":"Injection","sponsorNew":"Tessera Therapeutics \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Tessera Therapeutics \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Tessera Therapeutics","sponsor":"Serotiny","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Tessera Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tessera Therapeutics \/ Tessera Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Tessera Therapeutics \/ Tessera Therapeutics"},{"orgOrder":0,"company":"Tessera Therapeutics","sponsor":"ARPA-H","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Tessera Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Tessera Therapeutics \/ ARPA-H","highestDevelopmentStatusID":"4","companyTruncated":"Tessera Therapeutics \/ ARPA-H"},{"orgOrder":0,"company":"Tessera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"TSRA-196","moa":"A1AT","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Tessera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tessera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tessera Therapeutics \/ Undisclosed"}]